DeOndra Dixon INCLUDE Project Act of 2025: NIH to Launch Coordinated Lifespan Research for Down Syndrome

The DeOndra Dixon INCLUDE Project Act of 2025 formally establishes a dedicated, federally coordinated research program within the National Institutes of Health (NIH). Named the INCLUDE Project (short for Investigation of Co-occurring conditions across the Lifespan to Understand Down syndromE), this legislation mandates that the NIH Director oversee high-risk, high-reward research into how an extra copy of chromosome 21 affects human health. The bill requires the NIH to prioritize studies that follow participants through their entire lives, specifically focusing on why conditions like Alzheimer’s and autoimmune disorders are more common in this population. It also demands an expansion of clinical trials tailored to the specific needs of individuals with Down syndrome, moving beyond general studies to find treatments for daily living challenges.

A Lifespan Strategy for Health

For families navigating a Down syndrome diagnosis, medical care often feels like a series of disconnected appointments. This bill changes the game by requiring the NIH to study the biological mechanisms of growth delays and behavioral differences across a person's whole life (Section 2). Imagine a toddler with Down syndrome today; under this act, research wouldn't just look at their immediate developmental milestones, but would track how their unique biology interacts with aging. By focusing on biomarkers—think of these as biological red flags—doctors could eventually predict and treat co-occurring conditions like heart defects or respiratory issues before they become emergencies. It’s about moving from reactive medicine to a proactive roadmap for long-term health.

Coordinating the Experts

One of the biggest hurdles in government research is the "silo" effect, where different departments don't talk to each other. This bill tackles that head-on by requiring the NIH Director to ensure all institutes and centers coordinate their efforts and avoid duplicating work. For a researcher or a biotech startup, this means a more streamlined path to federal support for novel drug therapies. The bill also mandates that the NIH consult with patient advocacy groups, ensuring that the people actually living with Down syndrome have a seat at the table when research priorities are set. It’s a move toward “nothing about us without us,” making sure the science serves the community’s actual needs rather than just academic curiosity.

Accountability and Real-World Results

To make sure this isn't just another program that disappears into a bureaucratic black hole, the bill requires a report to Congress every two years. These reports must detail exactly which NIH centers are involved and, more importantly, highlight "real-world evidence" that can be used in clinical care (Section 2). For a physical therapist or a primary care doctor, this could mean faster access to updated clinical guidelines based on the latest trisomy 21 research. By linking federal funding to specific reporting on how research translates to patient care, the bill aims to turn laboratory discoveries into tangible improvements for quality of life, from better diagnostic tools to improved support for families.